10-K: Veradigm Inc. Files Annual Report, Faces Internal Control Challenges

Veradigm Inc. has filed its annual report for the fiscal year ended December 31, 2024, detailing a significant revenue decrease, substantial goodwill impairment, and ongoing material weaknesses in internal controls.

Summary

• Veradigm Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company reported a total revenue decrease of $31.6 million compared to the prior year, primarily driven by a $19.0 million drop in the Provider segment due to an isolated customer settlement in 2023.
• Gross profit also decreased by $39.3 million, attributed to lower revenue and increased hosting costs.
• Selling, general, and administrative expenses significantly increased by $68.5 million, largely due to higher consulting, audit, and legal services costs related to financial restatements and investigations.
• A substantial goodwill impairment of $108.0 million was recorded, primarily resulting from a decline in the market value of the company's common stock.
• The company's independent registered public accounting firm issued an adverse opinion on its internal control over financial reporting, identifying material weaknesses in management review controls, revenue recognition accounting, measurement of expected credit losses, financial reporting, and valuation.
• The company is actively implementing a remediation plan to address these internal control deficiencies, with substantial completion expected in 2027.
• Veradigm's common stock is currently trading on the OTC Expert Market after being delisted from Nasdaq.
• The company repurchased a significant portion of its convertible notes in 2025, reducing outstanding principal to $20 thousand.
• New leadership appointments were made, including Donald Trigg as CEO and Christian Greyenbuhl as CFO.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the significant revenue decline, substantial goodwill impairment, widening net loss, and critical material weaknesses in internal controls, despite new leadership and a remediation plan.

Positives

• The company has a substantial cash and cash equivalents balance of $294.3 million as of December 31, 2024, which is expected to support operations.
• New leadership has been appointed, including a new CEO and CFO, signaling a strategic reset.
• The company is actively working on a remediation plan to address internal control weaknesses.
• Significant progress has been made in repurchasing convertible notes, reducing outstanding debt.
• The company has entered into new credit facilities providing $100 million in liquidity.

Negatives

• Total revenue decreased by $31.6 million for the year ended December 31, 2024, compared to the prior year.
• Gross profit decreased by $39.3 million, with a decline in gross margin from 54.6% to 50.8%.
• Selling, general, and administrative expenses increased by $68.5 million, significantly impacting profitability.
• A goodwill impairment of $108.0 million was recorded, reflecting a decline in the company's market value.
• The company received an adverse opinion from its auditor regarding its internal control over financial reporting, citing multiple material weaknesses.
• The company's common stock was delisted from Nasdaq and currently trades on the OTC Expert Market, limiting liquidity and investor access.
• Net loss from continuing operations was $291.6 million for the year ended December 31, 2024, compared to a net income of $49.2 million in the prior year.
• The company incurred significant legal and consulting expenses related to past accounting issues and investigations.

Risks

• Failure to successfully complete the remediation plan for internal control weaknesses could continue to impair the company's ability to produce accurate financial statements and could have reputational impacts.
• The delisting from Nasdaq and trading on the OTC Expert Market limits liquidity, reduces investor access, and may continue to adversely affect the price of the company's common stock.
• The company's business is subject to significant risks related to the highly regulated healthcare industry, including potential changes in laws and regulations.
• Intense competition in the healthcare IT market and rapid technological changes pose a risk to the company's ability to compete effectively.
• Disruptions of information technology systems or breaches of information security could materially and adversely affect the company's business, financial condition, and operating results.
• The company faces risks related to its significant indebtedness, including covenants in its credit agreement that impose significant operating and financial restrictions.
• The company's ability to attract and retain key personnel is critical, and failure to do so could adversely affect its business.
• The company is subject to ongoing litigation and investigations, which could result in significant costs, penalties, and reputational damage.

Future Outlook

The company is focused on executing its 'reset, recover, reignite' transformation strategy, which includes optimizing its business portfolio, investing in higher-growth opportunities, improving operational efficiency, and accelerating AI adoption. Management believes its current cash position and future cash flows will be sufficient to support operations and contractual commitments for the next 12 months. However, the company acknowledges the need to become current with SEC reporting obligations and relist its common stock on a national securities exchange.

Management Comments

• Management believes that continued investment in AI across its Provider, Payer, and Life Science businesses will enable the development of more differentiated products, support higher quality, lower cost care, and position the company as a higher-margin technology and data products business over time.
• The company plans to continue to prioritize remediating identified material weaknesses, becoming current with SEC reporting obligations, executing its strategy, and relisting its common stock on a national securities exchange.

Industry Context

StockSavvy.ai notes that Veradigm's filing reflects broader industry trends in healthcare technology, including the increasing adoption of AI, the ongoing shift towards value-based care, and the persistent challenges of cybersecurity and regulatory compliance. The company's strategic focus on independent physician practices and data analytics aligns with key industry drivers.

Comparison to Industry Standards

• Veradigm's revenue decline of 5.1% in 2024 contrasts with the general growth observed in the healthcare IT sector, which has seen increased demand for digital health solutions and data analytics.
• The company's significant goodwill impairment of $108.0 million, driven by stock price decline, highlights the market's valuation challenges for companies undergoing significant operational and financial restatements, a situation not uncommon in the sector but particularly pronounced for Veradigm.
• The material weaknesses in internal controls identified by BDO USA, P.C. are a serious concern. While many companies in the tech sector face control challenges during periods of rapid growth or transformation, the breadth and nature of Veradigm's identified weaknesses (management review, revenue recognition, credit loss measurement, financial reporting, valuation) suggest a more systemic issue that requires substantial remediation efforts, potentially impacting investor confidence compared to peers with more robust control environments.
• Veradigm's strategy to leverage AI through its ScienceIO acquisition is in line with industry leaders like Epic Systems Corporation and Cerner (now Oracle Health), who are heavily investing in AI for clinical decision support, operational efficiency, and personalized medicine. However, Veradigm's ability to capitalize on this trend is currently hampered by its internal control deficiencies and delisted stock status.

Management Changes

Corporate Governance

Legal Proceedings

• Juliet Wells v. Richard J. Poulton, et al. - Putative shareholder derivative complaint alleging breach of fiduciary duty, unjust enrichment, and insider trading.
• John M. Erwin v. Veradigm Inc., et al. - Putative securities class action alleging materially false or misleading statements and omissions regarding business, financial results, and internal controls.
• Altera Digital Health, Inc. v. Veradigm Inc - Altera alleges breach of contract related to financial statement representations and warranties, seeking $50 million.
• Tony Goodrum v. Veradigm, Inc. - Putative class action alleging negligence, breach of contract, and unjust enrichment due to a data compromise incident.
• Practice Fusion resolved Anti-Kickback Statute and False Claims Act allegations with the DOJ in 2020 and subsequently faced state AG investigations and civil litigation related to pain management alerts sponsored by Purdue Pharma.
• McKesson CIDs related to Horizon Clinicals and Paragon software certification, with McKesson agreeing to indemnify Veradigm for certain amounts paid to the government.
• SEC investigation concluded in February 2026 with no enforcement action against the Company.

Related Party Transactions

• Registration Rights Agreement and Confidentiality Agreement entered into with Stonehill Capital Management LLC in connection with the appointment of Jonathan Sacks to the Board.
• Transactions with investees who are customers or vendors, including revenue recognition and contract assets with related parties.
• Business conducted with an outside data center vendor where a Company executive served on the vendors advisory board from May 2022 to December 2023.

Stakeholder Impact

• Shareholders: Negative impact due to revenue decline, net loss, goodwill impairment, delisting from Nasdaq, and ongoing internal control weaknesses. However, new leadership and remediation efforts may offer future recovery potential.
• Employees: Potential impact from ongoing remediation efforts, workforce optimization actions, and the need to attract and retain talent amidst financial challenges and leadership changes. Equity awards are a key retention tool.
• Customers: Continued reliance on Veradigm's solutions for healthcare operations. Potential concerns may arise from the company's financial stability and internal control issues, though the company states its primary network and customer systems were not directly affected by recent cybersecurity incidents.
• Creditors: The company has secured new financing through a $100 million senior secured term loan credit facility, but the covenants impose significant restrictions. The repurchase of convertible notes reduces debt obligations.

Next Steps

• Continue implementing the remediation plan to address material weaknesses in internal controls.
• Work towards becoming current with SEC reporting obligations.
• Seek to relist the company's common stock on a national securities exchange.
• Execute the 'reset, recover, reignite' transformation strategy.
• Integrate acquired companies (Koha Health and ScienceIO) and leverage their capabilities.

Key Dates

Recommendation

Veradigm's filing presents a mixed picture. While the company has new leadership and is actively addressing significant internal control weaknesses and debt obligations, the substantial revenue decline, widening net loss, and ongoing material weaknesses in financial reporting are considerable concerns. The delisting from Nasdaq further exacerbates these issues. The company's strategy to leverage AI and data analytics is positive, but its execution is hampered by the current operational and financial challenges. A 'hold' recommendation reflects the potential for recovery driven by strategic initiatives and remediation efforts, balanced against the significant risks and uncertainties that remain.

Keywords

Veradigm, SEC Filing, 10-K, Annual Report, Healthcare Technology, EHR, Financial Results, Internal Controls, Goodwill Impairment, Delisting, CEO Appointment, CFO Appointment, Convertible Notes, Credit Facility